A world leader in side effect management
Chemotherapy-induced hair loss and chemotherapy-induced peripheral neuropathy are widely recognised as the most traumatic side effects associated with cancer treatment, and yet they are still often believed to be inevitable. Paxman are changing that.
Paxman’s commitment to supporting patients goes beyond technological innovation; it’s about fostering a holistic brand experience where patients are informed, connected, and empowered in their chemotherapy journey. As an investor, you’re not just supporting a company; you’re joining us in giving a degree of control to patients around the world.
What we do
Paxman are world leaders in chemotherapy side effect management, with the goal of creating a world where hair loss and nerve damage induced by chemotherapy are no longer an issue. We strive for a world where everyone - regardless of geography, ethnicity, financial situation, gender, or treatment regimen – has access to the effective, trusted cryotherapy solutions they need to prevent the side effects of chemotherapy
Learn more
Financial information
Read the latest financial reports from the Paxman Group. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Learn more
Investing in Paxman
Paxman treats thousands of patients each year and has 6,000+ scalp cooling systems installed in more than 65 countries worldwide, and has now launched a device to meet the unmet clinical need for peripheral neuropathy prevention. We are helping to manage the trauma and life-long damage of chemotherapy side effects. By investing in Paxman, you're not just supporting a company; you're joining us in making a difference.
Learn moreLatest from Paxman
Paxman Announces Official Commercial Launch of First-of-Its-Kind Neuropathy System as Scientific Evidence Highlights Significant Unmet Need in Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Read morePaxman Secures First UK Orders for Neuropathy System Ahead of Commercial Launch to Address the Significant Unmet Clinical Need of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Read more25+
years of pioneering side effect management technology
65
markets worldwide
100K+
cancer patients have scalp cooled across the world